



## Personalized Radiotherapy

Guest Editors:

**Prof. Dr. Julian Malicki**

1. Electroradiology Department,  
Poznan University of Medical  
Sciences, 61-688 Poznan, Poland  
2. Greater Poland Cancer Centre,  
Department of Medical Physics,  
61-688 Poznan, Poland

**Prof. Dr. Petera Jiří**

Department of Oncology and  
Radiotherapy, Faculty of  
Medicine in Hradec Králové and  
University Hospital Hradec  
Králové, Charles University, 500  
05 Hradec Králové, Czech  
Republic

Deadline for manuscript  
submissions:

**closed (30 November 2022)**

### Message from the Guest Editors

Radiotherapy is one of the main methods of cancer treatment. Since the introduction of radiotherapy treatment, radiation oncologists and medical physicists have adapted radiation beam parameters to tumour size, shape, and localization in the body willing to eliminate cancer and keep healthy organs intact. Biologists have contributed significantly, providing knowledge on tumour and normal tissue sensitivity and factors influencing their response to radiation. The advancement in science, developments in technology, and increasing clinical evidence today allow to tailor treatment to each patient. Today, we adapt therapy to tumour properties, its morphology (dominant lesions) and metabolic properties, with emphasis on genetic factors and the underlying immunological status. We also try to reduce low doses, which occur in peripheral organs.

We welcome papers dealing with all aspects aimed to widen the knowledge on the tumour and healthy organ response to radiation in concomitance to other anticancer treatments or pre-existing factors. In particular, we invite papers focusing on radiotherapy individualization, leading to better results and improved patient comfort and safety.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)